Methotrexate (Cadila Healthcare Limited)
Welcome to the PulseAid listing for the Methotrexate drug offered from Cadila Healthcare Limited. This Folate Analog Metabolic Inhibitor [EPC],Folic Acid Metabolism Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Cadila Healthcare Limited |
NON-PROPRIETARY NAME: | Methotrexate |
SUBSTANCE NAME: | METHOTREXATE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Folate Analog Metabolic Inhibitor [EPC],Folic Acid Metabolism Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | ANDA |
START MARKETING DATE: | 2017-02-09 |
END MARKETING DATE: | 0000-00-00 |
Methotrexate HUMAN PRESCRIPTION DRUG Details:
Item Description | Methotrexate from Cadila Healthcare Limited |
LABELER NAME: | Cadila Healthcare Limited |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 2.5(mg/1) |
START MARKETING DATE: | 2017-02-09 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 70771-1058_3add9f96-1e15-4c3e-88e0-03948601765e |
PRODUCT NDC: | 70771-1058 |
APPLICATION NUMBER: | ANDA207812 |
Other METHOTREXATE Pharmaceutical Manufacturers / Labelers: